Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Pfizer reports new class of muscarinic agonists

Aug. 30, 1996

CRM-1.13.1: Nicotinic agonist based on lobeline

Aug. 30, 1996

Memantine enters phase I for AIDS-related dementia, painful peripheral neuropathies

Aug. 30, 1996

Synapton phase III trials concluded

Aug. 30, 1996

Prednisone suppresses acute phase in AD patients

Aug. 30, 1996

Botulinum toxin effective in treating writer's cramp

Aug. 30, 1996

Botulinum toxin effective in reducing upper limb spasticity

Aug. 30, 1996

Roche files for approval of Tasmar

Aug. 30, 1996

Tegretol-XR launched in U.S.

Aug. 30, 1996

CGP-25454 tested in healthy volunteers

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...